BIB vs. ARKG
Compare and contrast key facts about ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
BIB and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010. ARKG is an actively managed fund by ARK Investment Management. It was launched on Oct 31, 2014.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIB or ARKG.
Key characteristics
| BIB | ARKG | |
|---|---|---|
| YTD Return | -14.15% | -29.87% |
| 1Y Return | -9.79% | -19.87% |
| 3Y Return (Ann) | -19.07% | -36.98% |
| 5Y Return (Ann) | -0.71% | -6.39% |
| Sharpe Ratio | -0.37 | -0.52 |
| Daily Std Dev | 33.04% | 40.00% |
| Max Drawdown | -67.24% | -80.10% |
| Current Drawdown | -56.03% | -79.41% |
Correlation
The correlation between BIB and ARKG is 0.79, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
BIB vs. ARKG - Performance Comparison
In the year-to-date period, BIB achieves a -14.15% return, which is significantly higher than ARKG's -29.87% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BIB vs. ARKG - Expense Ratio Comparison
BIB has a 0.95% expense ratio, which is higher than ARKG's 0.75% expense ratio.
Risk-Adjusted Performance
BIB vs. ARKG - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIB vs. ARKG - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.16%, while ARKG has not paid dividends to shareholders.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.16% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 1.94% | 1.34% |
Drawdowns
BIB vs. ARKG - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum ARKG drawdown of -80.10%. Use the drawdown chart below to compare losses from any high point for BIB and ARKG. For additional features, visit the drawdowns tool.
Volatility
BIB vs. ARKG - Volatility Comparison
ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG) have volatilities of 10.00% and 10.52%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.